These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26872382)

  • 41. Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
    Connell CM; Shibata A; Tookman LA; Archibald KM; Flak MB; Pirlo KJ; Lockley M; Wheatley SP; McNeish IA
    J Clin Invest; 2011 Apr; 121(4):1283-97. PubMed ID: 21383502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
    Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
    Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
    J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
    Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
    Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ
    Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
    Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
    Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
    Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
    Kostova Y; Mantwill K; Holm PS; Anton M
    Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation.
    Liu S; Bekker-Jensen S; Mailand N; Lukas C; Bartek J; Lukas J
    Mol Cell Biol; 2006 Aug; 26(16):6056-64. PubMed ID: 16880517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
    Eisenberg DP; Adusumilli PS; Hendershott KJ; Yu Z; Mullerad M; Chan MK; Chou TC; Fong Y
    J Gastrointest Surg; 2005 Nov; 9(8):1068-77; discussion 1077-9. PubMed ID: 16269377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.
    Puig-Saus C; Laborda E; Rodríguez-García A; Cascalló M; Moreno R; Alemany R
    Cancer Gene Ther; 2014 Feb; 21(2):68-73. PubMed ID: 24434571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modification of oncolytic adenovirus and its application in cancer therapy.
    Liang Y; He J; Zhao Y
    Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.
    Rovira-Rigau M; Raimondi G; Marín MÁ; Gironella M; Alemany R; Fillat C
    Mol Ther; 2019 Jan; 27(1):230-243. PubMed ID: 30341009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.
    Yoon AR; Hong J; Yun CO
    Oncotarget; 2015 Oct; 6(33):34875-91. PubMed ID: 26430798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
    Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
    Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
    Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
    Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
    Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z
    Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.